Developer docs
API playgroundTry for free, no card

Search company profiles

EirGenix

Full company profile

uuid0004yak

Namestring
EirGenix
Legal namestring
EirGenix, Inc.
Websiteurl
eirgenix.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

EirGenix, Inc. is a Taipei-based biopharmaceutical company operating two business units: a contract development and manufacturing organization (CDMO) and a biosimilar product development unit. The CDMO business provides end-to-end services including cell line development, upstream and downstream process development, analytical and quality control, cGMP mammalian manufacturing (CHO-based, 50L to 2,000L single-use bioreactors), cGMP microbial fermentation (E. coli and Pichia pastoris, 20L to 1,500L), and integrated antibody-drug conjugate (ADC) and bioconjugate services through a strategic partnership with Formosa Laboratories for high-potency payloads. EirGenix serves pharmaceutical and biotech clients globally and operates two cGMP-certified facilities in Taiwan (Xizhi for pre-clinical/pilot work, Zhubei for late-stage clinical and commercial supply) with combined annual antibody output capacity of up to 1,000 kg and 12 x 2,000L single-use bioreactors in Zhubei.

The proprietary product business is built around HER2-targeted biosimilars, anchored by the approved EG12014 Trastuzumab biosimilar (EIRGASUN/HERWENDA), which received Taiwan FDA approval in 2023 and European Commission marketing authorization in November 2023, and EG1206A Pertuzumab biosimilar, which received Phase III trial waivers from FDA/EMA in 2025. The broader pipeline includes ADC biosimilars (Kadcyla and Enhertu analogues), Phesgo and Atezolizumab biosimilars, a CD38 daratumumab biosimilar, a recombinant human hyaluronidase (rHuPH20), and supporting platform products such as CRM197 and HRV3C Protease. The technology platform extends to the licensed HiCB continuous bioprocessing system from Transcenta and proprietary cell line capabilities across CHO-K1, CHO-S, CHO-DG44, CHO-C, CHOZN, NS0, HEK293, PER.C6, and Hybridoma lines.

EirGenix generates revenue through three primary streams: (1) CDMO service fees for development and manufacturing engagements billed to pharma/biotech clients, (2) one-time biosimilar product supply revenues routed through licensing partners, and (3) licensing-related inflows including upfront payments, milestone payments, and ongoing profit-share or royalty arrangements with commercialization partners, most notably the global exclusive deals with Sandoz AG covering EG12014 (signed April 2019) and EG1206A (signed November 2025) for all territories outside Taiwan and selected Asian markets. Pricing is quote-based and not publicly disclosed. The company is publicly traded on Taiwan's TPEx under ticker 6589 and had NT$1,005 million (approximately US$31 million) of revenue in 2025.

Short descriptiontext

EirGenix is a Taipei-based biopharmaceutical CDMO and biosimilar developer operating two Taiwan cGMP facilities, offering mammalian and microbial biologics manufacturing, ADC services, and a HER2 biosimilar portfolio licensed globally to Sandoz.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersTaipei, Taiwan
HQ citystring
Taipei
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologics contract manufacturing, biosimilar development services, cell line development, antibody drug conjugates, cGMP biomanufacturing
Industry5 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical CDMO & Biosimilar Development
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing organization providing end-to-end services from cell line development to commercial-scale GMP manufacturing of biologics for pharmaceutical and biotech clients. Revenue derived from service fees across mammalian and microbial platforms.

eirgenix.com
2Biosimilar Product Sales
TypeOne Time License
Description

EirGenix develops and manufactures proprietary biosimilar products including Trastuzumab (EIRGASUN/HERWENDA) which has received marketing authorization. Products are commercialized through partners in global markets.

eirgenix.com
3Licensing Royalties and Milestones
TypeLicensing Royalties
Description

Upfront payments, milestone payments, and ongoing royalties from licensing agreements with pharmaceutical partners. Notable deals include up to USD 152 million from Sandoz for EG1206A plus profit sharing upon launch.

eirgenix.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

EirGenix is a biopharmaceutical CDMO providing end-to-end contract development and manufacturing services for biologics — including cell line development, process development, analytical and quality control, cGMP manufacturing (mammalian CHO and microbial E. coli/Pichia systems), and ADC and bioconjugate services — from pre-clinical through commercial scale. The company also develops biosimilars (notably HER2-targeted Trastuzumab and Pertuzumab biosimilars), which are commercialized globally through licensing partnerships with companies such as Sandoz AG. Two cGMP manufacturing facilities in Taiwan (Xizhi and Zhubei) hold regulatory approvals from US FDA, EMA, PMDA, TFDA, and TGA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • HiCB platform delivers 10-15 fold productivity increase and reduces cost of goods by at least 50% compared to conventional fed-batch processes
+3 more records
Product overview1 text field

EirGenix operates as a biopharmaceutical CDMO and biosimilar developer with two distinct business units: a CDMO unit providing contract development and manufacturing services, and a Product Development unit focused on biosimilars. The CDMO services include Cell Line Development, Process Development, Analytical & Quality Control, cGMP Manufacturing (both mammalian and microbial systems), and ADC & Bioconjugates services. The product pipeline comprises HER2-targeted biosimilars including EG12014 (EIRGASUN®/HERWENDA® Trastuzumab, commercially available), EG1206A (Pertuzumab, Phase III waived), and several ADC biosimilars (EG12043 Kadcyla, EG12170 Trastuzumab-deruxtecan), plus supporting platform products (HRV3C Protease, CRM197). The company operates two cGMP-compliant facilities in Taiwan (Xizhi and Zhubei) with combined mammalian capacity of twelve 2,000L single-use bioreactors.

Product and service10 records
1EIRGASUN/HERWENDA (EG12014) Trastuzumab Biosimilar
CategoryBiosimilar (Oncology)
Description

A Trastuzumab biosimilar approved for treatment of HER2-positive early-stage breast cancer, metastatic breast cancer, and gastric cancer. Marketed in Taiwan under the EIRGASUN® brand and licensed to Sandoz globally (excluding Taiwan, China, Russia, and certain Asian countries) under HERWENDA®. Intended for healthcare providers treating HER2-positive cancers.

2Cell Line Development Services
CategoryCDMO Service
Description

Comprehensive cell line development services from DNA to stable producer cell lines for mammalian (CHO-K1, CHO-S, CHO-DG44, HEK293) and microbial (E. coli, Pichia) systems. Generates high-productivity cell lines within 19 weeks for mammalian systems. Served to pharmaceutical and biotech clients building biologics programs.

3Process Development Services
CategoryCDMO Service
Description

End-to-end process development services covering upstream and downstream processing. Upstream capabilities include media screening and feeding optimization for mammalian (3L–50L) and microbial (2L–20L) systems; downstream includes chromatography, ultrafiltration, and lyophilization. Supports pre-clinical to commercial readiness.

4Analytical & Quality Control Services
CategoryCDMO Service
Description

Comprehensive analytical services supporting biopharmaceutical development through GMP manufacturing, including method development, validation, protein characterization, and release testing using SEC-HPLC, SPR, cell-based assays, and LC/MS/MS. Serves CDMO clients requiring release and characterization support.

5cGMP Mammalian Manufacturing
CategoryCDMO Service
Description

cGMP manufacturing services for monoclonal antibodies, bispecific/trispecific antibodies, and ADCs using CHO cells. Facilities include 50L–2,000L single-use bioreactors and stainless steel bioreactors across the Xizhi (~10,000 sq ft) and Zhubei facilities with up to 1,000 kg annual antibody production capacity per line. Served to global pharma/biotech CDMO clients.

6cGMP Microbial Manufacturing
CategoryCDMO Service
Description

cGMP microbial fermentation services using E. coli and Pichia expression systems. Xizhi facility supports 20L–1,000L fermentation; Zhubei facility supports 30–1,500L scale-up. Capabilities include inclusion body processing and soluble protein manufacturing. Served to clients producing recombinant proteins, enzymes and plasmid DNA.

7ADC & Bioconjugates Services
CategoryCDMO Service
Description

Integrated ADC development and manufacturing services including monoclonal antibody development, high-potency chemical manufacturing (via strategic partner Formosa Laboratories), linker technology, and conjugation. Supports both cytotoxic and non-cytotoxic conjugates from small-scale (50–250g batches) to large-scale (1.5–3.0 kg batches). Served to oncology drug developers.

8HRV3C Protease
CategorySupporting Product / Research Tool
Description

Human Rhinovirus 3C protease available in GMP-grade and R&D-grade for precise removal of affinity tags from recombinant proteins under mild reaction conditions. Used in protein purification and structural studies. Targeted at biologics R&D and manufacturing groups.

9CRM197
CategorySupporting Product / Research Tool
Description

Cross Reacting Material 197, a non-toxic mutant of diphtheria toxin used as a vaccine carrier protein and for targeted cancer therapy applications. US FDA DMF Number available. Targeted at vaccine developers and oncology researchers.

10EG1206A Pertuzumab Biosimilar
CategoryBiosimilar (Oncology)
Description

A second-generation HER2-targeted monoclonal antibody biosimilar targeting Perjeta® (Pertuzumab) for HER2-positive breast cancer. Achieved Phase III trial waiver from FDA/EMA in October 2025, enabling accelerated regulatory pathway. Licensed to Sandoz AG for global commercialization (excluding Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, Philippines, and Japan) under a deal valued up to USD 152 million plus profit sharing.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-29
Description

Strategic collaboration and non-exclusive licensing agreement granting EirGenix access to Transcenta's Highly Intensified Continuous Bioprocessing (HiCB) platform including continuous perfusion and integrated hybrid continuous purification technologies. EirGenix plans to apply the HiCB platform to serve its CDMO clients pursuing intensified and continuous manufacturing solutions. Transcenta receives upfront, milestone, and future royalty payments.

2Sandoz AG
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-12
Description

Second global exclusive licensing agreement for commercialization of EG1206A (Pertuzumab biosimilar), covering all territories except Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, Philippines, and Japan. EirGenix receives up to USD 152 million in upfront and milestone payments plus profit sharing upon launch. EirGenix responsible for development and manufacturing.

eirgenix.com
3Sandoz AG
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2019-04-30
Description

Global commercialization agreement for EG12014 (Trastuzumab biosimilar in both 150mg and 420mg formulations). EirGenix responsible for development and manufacturing; Sandoz holds commercialization rights for global markets excluding Taiwan, China, Russia, and certain Asian countries. Product has received EC approval and is under FDA BLA review.

eirgenix.com
4Formosa Laboratories
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-06-23
Description

Strategic partnership for ADC CMC integration services. Formosa Laboratories, a global leader in high-potency drug manufacturing, supplies quality active pharmaceutical ingredients (APIs) for ADCs including linkers and payloads. Combined capabilities provide end-to-end ADC development and manufacturing services.

eirgenix.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global biologics CDMO offering mammalian and microbial manufacturing services across multiple sites. Direct competitor for mAb and recombinant protein CDMO contracts with similar regulatory certification profile and therapeutic focus areas.

TypeDirect peer
Description

Asian-headquartered biologics CDMO with large-scale mammalian manufacturing capacity serving global pharma clients. Directly comparable to EirGenix in CDMO service offering, regulatory certifications (FDA/EMA), and target client base of pharma/biotech seeking mAb manufacturing partners.

TypeEmerging player
Description

European biosimilar developer with integrated development and manufacturing capabilities. Comparable biosimilar-focused business model and strong technical leadership, with overlapping therapeutic area focus including oncology biosimilars.

TypeDirect peer
Description

Global leader in biologics CDMO with end-to-end capabilities from cell line development to commercial manufacturing. Direct competitor in mammalian cell culture CDMO services, targeting the same pharma/biotech client base for mAb, bispecific, and recombinant protein manufacturing.

TypeDirect peer
Description

Global biologics CDMO with mammalian and microbial platforms supporting pre-clinical through commercial supply. Direct peer in biologics CDMO services targeting pharma clients, with comparable GMP certifications and large-scale bioreactor capacity.

TypeEmerging player
Description

Taiwan-based biologics CDMO offering mammalian and microbial contract manufacturing services. Regional competitor with similar focus on mAb and recombinant protein manufacturing for global pharma clients, sharing Asia-Pacific customer base.

TypeEmerging player
Description

Korean biosimilar developer with integrated manufacturing capabilities, similar business model combining biosimilar product development with in-house CDMO-like capacity. Comparable in HER2 biosimilar focus (Celltrion has its own biosimilar franchise) and Asian-headquartered biologics manufacturing footprint.

TypeBroad incumbent
Description

Large diversified CDMO with biologics capabilities among broader service offerings. Overlaps with EirGenix in mammalian cell-based biologics manufacturing and cell line development but serves a broader range of modalities and dosage forms.

TypeOthers
Description

Canadian-based generic and biosimilar manufacturer with a biologics division. Comparable biosimilar product development orientation and has produced talent (Klaus Martin) familiar with EirGenix's organizational model and biosimilar commercial strategy.

10Boehringer Ingelheim BioXcellence
TypeDirect peer
Description

Biologics CDMO division of Boehringer Ingelheim providing process development and GMP manufacturing for mAbs, recombinant proteins, and biosimilars. Competes directly for biosimilar development and manufacturing partnerships with similar end-to-end service model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EirGenix

Biopharmaceutical CDMO & Biosimilar Developmenteirgenix.com

EirGenix is a Taipei-based biopharmaceutical CDMO and biosimilar developer operating two Taiwan cGMP facilities, offering mammalian and microbial biologics manufacturing, ADC services, and a HER2 biosimilar portfolio licensed globally to Sandoz.

What EirGenix does

EirGenix, Inc. is a Taipei-based biopharmaceutical company operating two business units: a contract development and manufacturing organization (CDMO) and a biosimilar product development unit. The CDMO business provides end-to-end services including cell line development, upstream and downstream process development, analytical and quality control, cGMP mammalian manufacturing (CHO-based, 50L to 2,000L single-use bioreactors), cGMP microbial fermentation (E. coli and Pichia pastoris, 20L to 1,500L), and integrated antibody-drug conjugate (ADC) and bioconjugate services through a strategic partnership with Formosa Laboratories for high-potency payloads. EirGenix serves pharmaceutical and biotech clients globally and operates two cGMP-certified facilities in Taiwan (Xizhi for pre-clinical/pilot work, Zhubei for late-stage clinical and commercial supply) with combined annual antibody output capacity of up to 1,000 kg and 12 x 2,000L single-use bioreactors in Zhubei.

The proprietary product business is built around HER2-targeted biosimilars, anchored by the approved EG12014 Trastuzumab biosimilar (EIRGASUN/HERWENDA), which received Taiwan FDA approval in 2023 and European Commission marketing authorization in November 2023, and EG1206A Pertuzumab biosimilar, which received Phase III trial waivers from FDA/EMA in 2025. The broader pipeline includes ADC biosimilars (Kadcyla and Enhertu analogues), Phesgo and Atezolizumab biosimilars, a CD38 daratumumab biosimilar, a recombinant human hyaluronidase (rHuPH20), and supporting platform products such as CRM197 and HRV3C Protease. The technology platform extends to the licensed HiCB continuous bioprocessing system from Transcenta and proprietary cell line capabilities across CHO-K1, CHO-S, CHO-DG44, CHO-C, CHOZN, NS0, HEK293, PER.C6, and Hybridoma lines.

EirGenix generates revenue through three primary streams: (1) CDMO service fees for development and manufacturing engagements billed to pharma/biotech clients, (2) one-time biosimilar product supply revenues routed through licensing partners, and (3) licensing-related inflows including upfront payments, milestone payments, and ongoing profit-share or royalty arrangements with commercialization partners, most notably the global exclusive deals with Sandoz AG covering EG12014 (signed April 2019) and EG1206A (signed November 2025) for all territories outside Taiwan and selected Asian markets. Pricing is quote-based and not publicly disclosed. The company is publicly traded on Taiwan's TPEx under ticker 6589 and had NT$1,005 million (approximately US$31 million) of revenue in 2025.

EirGenix firmographics

Firmographics
Name
EirGenix
Legal name
EirGenix, Inc.
Website
https://eirgenix.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
EirGenix is a Taipei-based biopharmaceutical CDMO and biosimilar developer operating two Taiwan cGMP facilities, offering mammalian and microbial biologics manufacturing, ADC services, and a HER2 biosimilar portfolio licensed globally to Sandoz.
Ownership category
akta.pro rank

EirGenix industry classification

Industry
Product category
Biopharmaceutical CDMO & Biosimilar Development
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Biologics contract manufacturing
  • Biosimilar development services
  • Cell line development
  • Antibody drug conjugates
  • CGMP biomanufacturing

Where EirGenix is headquartered

Location

Headquarters

HQ city
Taipei
HQ country
Taiwan
HQ region
Asia

Offices3 records

Markets served

EirGenix business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. CDMO Services: Contract development and manufacturing organization providing end-to-end services from cell line development to commercial-scale GMP manufacturing of biologics for pharmaceutical and biotech clients. Revenue derived from service fees across mammalian and microbial platforms.
  2. Biosimilar Product Sales: EirGenix develops and manufactures proprietary biosimilar products including Trastuzumab (EIRGASUN/HERWENDA) which has received marketing authorization. Products are commercialized through partners in global markets.
  3. Licensing Royalties and Milestones: Upfront payments, milestone payments, and ongoing royalties from licensing agreements with pharmaceutical partners. Notable deals include up to USD 152 million from Sandoz for EG1206A plus profit sharing upon launch.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

EirGenix product offering

Product offering

Core offering

EirGenix is a biopharmaceutical CDMO providing end-to-end contract development and manufacturing services for biologics — including cell line development, process development, analytical and quality control, cGMP manufacturing (mammalian CHO and microbial E. coli/Pichia systems), and ADC and bioconjugate services — from pre-clinical through commercial scale. The company also develops biosimilars (notably HER2-targeted Trastuzumab and Pertuzumab biosimilars), which are commercialized globally through licensing partnerships with companies such as Sandoz AG. Two cGMP manufacturing facilities in Taiwan (Xizhi and Zhubei) hold regulatory approvals from US FDA, EMA, PMDA, TFDA, and TGA.

Product overview

EirGenix operates as a biopharmaceutical CDMO and biosimilar developer with two distinct business units: a CDMO unit providing contract development and manufacturing services, and a Product Development unit focused on biosimilars. The CDMO services include Cell Line Development, Process Development, Analytical & Quality Control, cGMP Manufacturing (both mammalian and microbial systems), and ADC & Bioconjugates services. The product pipeline comprises HER2-targeted biosimilars including EG12014 (EIRGASUN®/HERWENDA® Trastuzumab, commercially available), EG1206A (Pertuzumab, Phase III waived), and several ADC biosimilars (EG12043 Kadcyla, EG12170 Trastuzumab-deruxtecan), plus supporting platform products (HRV3C Protease, CRM197). The company operates two cGMP-compliant facilities in Taiwan (Xizhi and Zhubei) with combined mammalian capacity of twelve 2,000L single-use bioreactors.

Differentiator

Problem solved

Functional benefit

Products and services

  • EIRGASUN/HERWENDA (EG12014) Trastuzumab Biosimilar A Trastuzumab biosimilar approved for treatment of HER2-positive early-stage breast cancer, metastatic breast cancer, and gastric cancer. Marketed in Taiwan under the EIRGASUN® brand and licensed to Sandoz globally (excluding Taiwan, China, Russia, and certain Asian countries) under HERWENDA®. Intended for healthcare providers treating HER2-positive cancers.
  • Cell Line Development Services Comprehensive cell line development services from DNA to stable producer cell lines for mammalian (CHO-K1, CHO-S, CHO-DG44, HEK293) and microbial (E. coli, Pichia) systems. Generates high-productivity cell lines within 19 weeks for mammalian systems. Served to pharmaceutical and biotech clients building biologics programs.
  • Process Development Services End-to-end process development services covering upstream and downstream processing. Upstream capabilities include media screening and feeding optimization for mammalian (3L–50L) and microbial (2L–20L) systems; downstream includes chromatography, ultrafiltration, and lyophilization. Supports pre-clinical to commercial readiness.
  • Analytical & Quality Control Services Comprehensive analytical services supporting biopharmaceutical development through GMP manufacturing, including method development, validation, protein characterization, and release testing using SEC-HPLC, SPR, cell-based assays, and LC/MS/MS. Serves CDMO clients requiring release and characterization support.
  • cGMP Mammalian Manufacturing cGMP manufacturing services for monoclonal antibodies, bispecific/trispecific antibodies, and ADCs using CHO cells. Facilities include 50L–2,000L single-use bioreactors and stainless steel bioreactors across the Xizhi (~10,000 sq ft) and Zhubei facilities with up to 1,000 kg annual antibody production capacity per line. Served to global pharma/biotech CDMO clients.
  • cGMP Microbial Manufacturing cGMP microbial fermentation services using E. coli and Pichia expression systems. Xizhi facility supports 20L–1,000L fermentation; Zhubei facility supports 30–1,500L scale-up. Capabilities include inclusion body processing and soluble protein manufacturing. Served to clients producing recombinant proteins, enzymes and plasmid DNA.
  • ADC & Bioconjugates Services Integrated ADC development and manufacturing services including monoclonal antibody development, high-potency chemical manufacturing (via strategic partner Formosa Laboratories), linker technology, and conjugation. Supports both cytotoxic and non-cytotoxic conjugates from small-scale (50–250g batches) to large-scale (1.5–3.0 kg batches). Served to oncology drug developers.
  • HRV3C Protease Human Rhinovirus 3C protease available in GMP-grade and R&D-grade for precise removal of affinity tags from recombinant proteins under mild reaction conditions. Used in protein purification and structural studies. Targeted at biologics R&D and manufacturing groups.
  • CRM197 Cross Reacting Material 197, a non-toxic mutant of diphtheria toxin used as a vaccine carrier protein and for targeted cancer therapy applications. US FDA DMF Number available. Targeted at vaccine developers and oncology researchers.
  • EG1206A Pertuzumab Biosimilar A second-generation HER2-targeted monoclonal antibody biosimilar targeting Perjeta® (Pertuzumab) for HER2-positive breast cancer. Achieved Phase III trial waiver from FDA/EMA in October 2025, enabling accelerated regulatory pathway. Licensed to Sandoz AG for global commercialization (excluding Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, Philippines, and Japan) under a deal valued up to USD 152 million plus profit sharing.

Quantifiable outcome

  • HiCB platform delivers 10-15 fold productivity increase and reduces cost of goods by at least 50% compared to conventional fed-batch processes
  • +3 more outcomes

Companies that use EirGenix

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

EirGenix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

EirGenix partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Transcenta TherapeuticscoreTechnology or Integration · 29 December 2025Strategic collaboration and non-exclusive licensing agreement granting EirGenix access to Transcenta's Highly Intensified Continuous Bioprocessing (HiCB) platform including continuous perfusion and integrated hybrid continuous purification technologies. EirGenix plans to apply the HiCB platform to serve its CDMO clients pursuing intensified and continuous manufacturing solutions. Transcenta receives upfront, milestone, and future royalty payments.
  • Sandoz AGcoreOEM/ Whitelabel/ Licensing Partner · 12 November 2025Second global exclusive licensing agreement for commercialization of EG1206A (Pertuzumab biosimilar), covering all territories except Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, Philippines, and Japan. EirGenix receives up to USD 152 million in upfront and milestone payments plus profit sharing upon launch. EirGenix responsible for development and manufacturing.
  • Sandoz AGcoreOEM/ Whitelabel/ Licensing Partner · 30 April 2019Global commercialization agreement for EG12014 (Trastuzumab biosimilar in both 150mg and 420mg formulations). EirGenix responsible for development and manufacturing; Sandoz holds commercialization rights for global markets excluding Taiwan, China, Russia, and certain Asian countries. Product has received EC approval and is under FDA BLA review.
  • Formosa LaboratoriescoreStrategic or Co-development Partner · 23 June 2014Strategic partnership for ADC CMC integration services. Formosa Laboratories, a global leader in high-potency drug manufacturing, supplies quality active pharmaceutical ingredients (APIs) for ADCs including linkers and payloads. Combined capabilities provide end-to-end ADC development and manufacturing services.

Scale indicators6 records

Recent moves10 records

Expansion highlights6 records

EirGenix competitors and assessment

Company assessment

Direct peers

  • AGC Biologics: Global biologics CDMO offering mammalian and microbial manufacturing services across multiple sites. Direct competitor for mAb and recombinant protein CDMO contracts with similar regulatory certification profile and therapeutic focus areas.
  • Samsung Biologics: Asian-headquartered biologics CDMO with large-scale mammalian manufacturing capacity serving global pharma clients. Directly comparable to EirGenix in CDMO service offering, regulatory certifications (FDA/EMA), and target client base of pharma/biotech seeking mAb manufacturing partners.
  • WuXi Biologics: Global leader in biologics CDMO with end-to-end capabilities from cell line development to commercial manufacturing. Direct competitor in mammalian cell culture CDMO services, targeting the same pharma/biotech client base for mAb, bispecific, and recombinant protein manufacturing.
  • Lonza Group: Global biologics CDMO with mammalian and microbial platforms supporting pre-clinical through commercial supply. Direct peer in biologics CDMO services targeting pharma clients, with comparable GMP certifications and large-scale bioreactor capacity.
  • Boehringer Ingelheim BioXcellence: Biologics CDMO division of Boehringer Ingelheim providing process development and GMP manufacturing for mAbs, recombinant proteins, and biosimilars. Competes directly for biosimilar development and manufacturing partnerships with similar end-to-end service model.

Emerging players

  • Polpharma Biologics: European biosimilar developer with integrated development and manufacturing capabilities. Comparable biosimilar-focused business model and strong technical leadership, with overlapping therapeutic area focus including oncology biosimilars.
  • Mycenax Biotech: Taiwan-based biologics CDMO offering mammalian and microbial contract manufacturing services. Regional competitor with similar focus on mAb and recombinant protein manufacturing for global pharma clients, sharing Asia-Pacific customer base.
  • Celltrion: Korean biosimilar developer with integrated manufacturing capabilities, similar business model combining biosimilar product development with in-house CDMO-like capacity. Comparable in HER2 biosimilar focus (Celltrion has its own biosimilar franchise) and Asian-headquartered biologics manufacturing footprint.

Broad incumbents

  • Catalent: Large diversified CDMO with biologics capabilities among broader service offerings. Overlaps with EirGenix in mammalian cell-based biologics manufacturing and cell line development but serves a broader range of modalities and dosage forms.

Others

  • Apotex (Apobiologix): Canadian-based generic and biosimilar manufacturer with a biologics division. Comparable biosimilar product development orientation and has produced talent (Klaus Martin) familiar with EirGenix's organizational model and biosimilar commercial strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

EirGenix social profiles

Digital presence

EirGenix compliance and trust

Trust signal

Compliance6 records

EirGenix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EirGenix leadership team

Management profile

Number of profiles

Profiles9 records

EirGenix subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

EirGenix funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EirGenix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EirGenix

What does EirGenix do?

EirGenix is a biopharmaceutical CDMO providing end-to-end contract development and manufacturing services for biologics — including cell line development, process development, analytical and quality control, cGMP manufacturing (mammalian CHO and microbial E. coli/Pichia systems), and ADC and bioconjugate services — from pre-clinical through commercial scale. The company also develops biosimilars (notably HER2-targeted Trastuzumab and Pertuzumab biosimilars), which are commercialized globally through licensing partnerships with companies such as Sandoz AG. Two cGMP manufacturing facilities in Taiwan (Xizhi and Zhubei) hold regulatory approvals from US FDA, EMA, PMDA, TFDA, and TGA.

Is EirGenix a public or private company?

EirGenix is a public company. It is classified as public and is currently operating.

When was EirGenix founded?

EirGenix was founded in 2012. It employs 101 to 250 people.

Where is EirGenix based?

EirGenix is headquartered in Taipei, Taiwan, in the Asia region.

How does EirGenix make money?

Three revenue lines are on record. CDMO Services are the primary driver. The others are biosimilar Product Sales and licensing Royalties and Milestones.

Who are EirGenix's main competitors?

Direct peers on record are AGC Biologics, Samsung Biologics, WuXi Biologics, Lonza Group and Boehringer Ingelheim BioXcellence. Emerging players are Polpharma Biologics, Mycenax Biotech and Celltrion. Catalent is listed as a broad incumbent. Apotex (Apobiologix) is listed as an others.

Does EirGenix have an API?

No public API is recorded for EirGenix.

What industry is EirGenix in?

EirGenix's product category is Biopharmaceutical CDMO & Biosimilar Development. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestHCW Biologics - pays in full amounts owed to Eirgenix under settlement agreement on May 26, 2026 - SEC filingHCW Biologics paid in full amounts owed to Eirgenix under a settlement agreement on May 26, 2026, according to an SEC filing. The article provides no details on the settlement amount or the underlying dispute that led to the agreement. This appears to be a routine regulatory disclosure with no substantive information beyond the fact that payment was made.AijournEirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026EirGenix presented its HER2-positive breast cancer biosimilar portfolio and integrated CDMO service platform at BIO 2026 in San Diego, actively pursuing U.S. market partnerships through business matchmaking discussions. The company operates a dual-track growth strategy combining targeted biosimilar development with a flexible contract manufacturing model to capture oncology opportunities amid an expected $300 billion biologics patent cliff over the next decade. EirGenix is advancing multiple biosimilar candidates including trastuzumab, pertuzumab, and ADC biosimilars, positioning itself to leverage both the projected growth of the global breast cancer drug market from $36.6 billion in 2024 to $69.7 billion by 2033 and increasing global demand for biologics outsourcing.PR Newswire APACEirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026EirGenix presented its HER2-positive breast cancer biosimilar portfolio and integrated CDMO service platform at BIO 2026 in San Diego, actively pursuing U.S. market opportunities through business matchmaking and global partnership discussions. The company highlighted a dual-track growth strategy leveraging the projected expansion of the global breast cancer drug market from $36.6 billion in 2024 to $69.7 billion by 2033, alongside the approximately $300 billion in biologics expected to lose patent protection over the next decade. EirGenix reiterated its commitment to expanding its global footprint by advancing high-value biosimilar assets while leveraging its commercial-scale manufacturing platform to support global clients across the entire product lifecycle.PR NewswireEirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026EirGenix showcased its HER2-positive breast cancer biosimilar portfolio and integrated CDMO service platform at BIO 2026 in San Diego, actively pursuing U.S. market partnerships and global collaboration opportunities. The company is implementing a dual-track growth strategy to capitalize on the approximately $300 billion in biologics losing patent protection over the next decade and the increasing global demand for contract development and manufacturing services. The article positions EirGenix as seeking to strengthen its global footprint by advancing biosimilar assets while leveraging its commercial-scale manufacturing capabilities to support partners across the product lifecycle.MorningstarEirGenix Showcases Dual-Track Biosimilars and CDMO Strategy in U.S. Market Push at BIO 2026EirGenix presented its HER2-positive breast cancer biosimilar portfolio and integrated CDMO platform at BIO 2026, targeting U.S. market opportunities. The company highlighted a dual-track strategy combining biosimilar development with CDMO services, citing a global breast cancer drug market projected to grow from $36.6B to $69.7B by 2033.GeneOnline NewsTaiwan’s Biotech Leaders Double Down on AI and US Manufacturing: Inside Bora and EirGenix’s Strategic RoadmapsAt the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Taiwanese biotech companies Bora Pharmaceuticals and EirGenix unveiled strategic roadmaps transitioning from traditional contract manufacturing to AI-driven production and US-based operations, marking a qualitative shift for Taiwan's biotech sector. Bora Pharmaceuticals reported FY2025 revenue of $634 million with its CDMO division growing 53.8% year-over-year to over $340 million, driven by US capacity expansion through acquisitions of Upsher-Smith and Emergent BioSolutions' Maryland facility, while also acquiring Pyros Pharmaceuticals' vigabatrin franchise for infantile spasms treatment. EirGenix finalized a continuous manufacturing technology contract and disclosed that two exclusive global commercialization agreements with Sandoz for HER2-positive breast cancer biosimilars reached transaction values up to $152 million.BioSpaceTranscenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable BiologicsTranscenta Therapeutics has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc., granting EirGenix access to its Highly Intensified Continuous Bioprocessing (HiCB) platform for biologics manufacturing. Under the terms, Transcenta will receive substantial upfront payments, milestone payments, and future royalties, while EirGenix plans to leverage the platform to serve its CDMO clients and expand its biologics development capabilities. The partnership aims to improve manufacturing efficiency, reduce costs, and increase global patient access to affordable biologics.PR NewswireEirGenix unterzeichnete die kommerzielle Lizenzvereinbarung für sein zweites HER2-Biosimilar EG1206AEirGenix Inc. announced on November 12 the signing of a second global exclusive license agreement with Sandoz AG for the marketing of its independently developed breast cancer biosimilar EG1206A (Pertuzumab biosimilar to Roche Perjeta®), covering all territories except Taiwan, mainland China, Macau, South Korea, and several other Asian countries. Under the agreement, EirGenix will receive up to $152 million in upfront and milestone payments plus profit sharing upon product launch, while also strengthening the existing collaboration between the two companies on HER2 biosimilar development. EG1206A has completed its pharmacokinetic clinical study and received positive feedback from both the FDA and EMA confirming eligibility for a shortened development pathway waiving Phase III comparative efficacy studies.PR NewswireEirGenix ha firmado el acuerdo de licencia comercial para su segundo biosimilar de HER2, EG1206AEirGenix Inc. announced on November 12 the signing of a second global exclusive licensing agreement with Sandoz AG for the commercialization of its HER2-positive breast cancer biosimilar EG1206A (biosimilar of Roche's Perjeta®), covering all territories except Taiwan and several Asian countries. Under the terms of the agreement, EirGenix will receive up to $152 million in upfront and milestone payments, plus profit sharing and sales-based incentives, while remaining responsible for product development, manufacturing, and supply. The FDA and EMA have confirmed EG1206A qualifies for an abbreviated development pathway with exemption from Phase III comparative efficacy trials, representing a significant regulatory milestone for the biosimilar candidate.PR NewswireEirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206AEirGenix Inc. has entered into a second global exclusive licensing agreement with Sandoz AG for the commercialization of its breast cancer biosimilar EG1206A (Pertuzumab biosimilar to Roche's Perjeta®), covering all territories except Taiwan, certain Asian markets, and Japan. Under the agreement, EirGenix will receive up to USD 152 million in upfront and milestone payments, plus profit share and sales incentives upon launch, while remaining responsible for product development, manufacturing, and supply. The biosimilar received positive feedback from both the U.S. FDA and EMA, confirming qualification for an abbreviated development pathway with a waiver of Phase III comparative efficacy trials, marking a significant regulatory milestone for the product.